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Objeaives. This study used a meta-analysis toexamine HLA-DR 
frequencies in rheumatic heart disease and prospectively exam- 
ined other class 11 allelic disease associations. 
Background. Studies of rheumatic heart disease have reported 
HLA class II allelie associations, but these are inconsistent. 
Methods. A recta-analysis combined all known (n = 10) studies 
to determine disease risk associated with HLA-DR antigen expres- 
sion. Meta-analysis of studies grouped by ethnic derivation of 
subjects was also performed. The present study also examined 
DQA, DQB and DPB allele frequencies by DNA.bnsed strategies. 
Results. Meta-analysis howed a significant negative disease 
association with DR5 (odds ratio [OR] 0.67, p < 0.00003) for all 
combined studies. Among black patients, DRI was increased (OR 
2.80, p < 0.004); DR6 was increased (OR, 2.03, p < 0.003); and 
DR 8 was decreased (OR 0.32, p < 0.02). Among Eastern Indian 
patients, DR3 was increased (OR 2A4, n < 0.00003), with 
decreased expression for DR2 (OR 0.31, p < 0.00001) and DR5 
(OR 0.52, p < 0.05). DR4 was increased among .American whites 
(OR 1.74, p < 0.03), although there was significant hetei~geneity 
among studies of whites. DQA, DQB and DPB allele frequencies 
were similar for control subjects and patients. 
Condusions. Our findings support an association between 
major histocompatibility complex class II alleles and risk for 
rheumatic heart disease. However, heterogeneity in associations 
was observed among different ethnic and racial groups; regional 
and temporal differences in streptococcal outbreaks may com- 
pound this heterogeneity. Further studies are necessary to eluci- 
date the respective contributions of these variables. 
(J Am Coil Cardio11995;26:452-7) 
Associations have been described between the presence of 
certain HLA alleles and increased risk for some diseases either 
having an autoimmune etiology or presenting with autoim- 
mune features. Most of these HLA-disease associations were 
described before an understanding of the role of major histo- 
compatibility complex antigens in the induction of immune 
responses was appreciated. In recent years, products of genes 
within the major histocompatibility complex region have been 
shown to be involved in the presentation of foreign as well as 
self antigens to the immune system. With this discovery, a 
physiologic basis was provided that may explain the association 
between major histocompatibility complex alleles and disease 
onset or progression. 
Three-dimensional cq,staUographic analysis (1) has shown 
that the structure of the major histocompatibility complex class 
II molecules includes a groove in which peptides to be 
presented to the immune system are bound. Sequence poly- 
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morphism within this peptide-binding groove has been pro- 
posed to be a controlling factor in peptide presentation and 
may provide an explanation for the associations between HLA 
alleles and disease (2). Indeed, it has been shown (3) that 
HLA-DR alleles exhibit specificity with respect o peptides 
that are bound. Additionally, polymorphic genes, the products 
of which are involved in the processing and transport of 
intracellular peptides, have been located within the major 
histocompatibility complex region (4). Thus, the uniquely 
individual capacity to mount an immune response to a foreign 
(or self) peptide may be explained by differences in genes 
located within the major bistocompatibility complex. 
Rheumatic heart disease is a disease with autoimmune 
features whose pathophysiology is incompletely understood. In
rheumatic heart disease, as for most autoimmune diseases, 
class II alleles have shown a stronger correlation with risk than 
class I alleles, but studies have given inconsistent results. 
Specifically, we and others previously identified a putative 
association between rheumatic heart disease and HL~-DR4 
(5-7). Still others have associated isease with DR3 (8-10), 
DR7 (8,11), DR1 (12), DR2 (7,10), DRw6 (12) and DQw2 (9). 
Given the seeming diversity of results relating class II 
alleles and risk for rheumatic heart disease, we sought to 
construct an overview of these associations by performing a
meta-analysis combining all known HLA (class II)--rheumatic 
heart disease association studies. Meta-analysis a statistical 
method in which information collected in multiple indepen- 
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dent (although commensurable) investigations is combined to 
increase the power to discern real from spurious associations. 
In the present investigation we used this method to assess 
disease-HLA DR associations both globally (combining all 
known studies) and also within genetically similar ethnic 
groups. 
We also attempted toconfirm prospectively our previously 
reported association between HLA-DR4 and rheumatic heart 
disease. We included testing for associations with alleles of the 
other class II loci (DP and DQ). These loci were included 
because of the possibility that the diversity of reported DR 
associations might be. explained by linkage of the susceptibility 
gene(s) to class II loci other than DR. in the present study, 
typing for DR alleles was done by serologic methods to 
maintain methodologie consistency among all of the studies 
that were included in the recta-analysis. However, DP and DQ 
alleles were not included in the meta-analysis; therefore, we 
chose to identify these alleles using a more specific DNA-based 
strategy. This method avoids potential technical problems 
associated with serologic typing and has the additional advan- 
tage of being able to distinguish alleles that are seroiogically 
identical but that may differ with respect o genotype and 
peptide presentation (13). 
Methods 
Meta.analysis of published studies. Studies of DR associ- 
ations with rheumatic heart disease were collected from pub- 
lished reports known to us, supplemented by other studies 
identified in the bibliographies of these studies and by an 
independent Medline search of published medical reports. All 
studies that provided DR typing of patients with rheumatic 
heart disease c.nd concurrent population control subjects were 
used. Ten studies (the present prospective study and nine 
published reports) were formally combined in a recta-analysis. 
The pooled risk estimates were computed using the method of 
Mantel-Haenszel (14,15). 
Fo~" each study, odds ratios along with their 95% confidence 
intervals were calculated for alleles DR1 to DR9. The 95% 
confidence intervals for the odds ratio (OR) were constructed 
as follows: 
95% CI = exp{ln(O"R) +- 1.96 ~/Var[ln(O-R)]}, 
where 
1 
Vat[In(O-R)] ~- Er=tl/tl/sti + 1/fti + I/S~ + l/f¢~' 
and n = total number of studies; i = study number (where i = 
1 to n); sti = number of disease-free subjects with a given 
marker; fti = number of subjects with disease with a giv- 
en marker; sei = number of disease-free subjects without a 
given marker; and fci = number of subjects with disease 
without a given marker (15,16). 
Odds ratios were used to measure the strength of associa- 
tion between the occurrence of rheumatic heart disease and a 
given DR allele. For each allele, an overall meta-analysis was 
performed on the odds ratios obtained from all studies. 
Meta-analysis was also performed on subsets that combined 
studies with test subjects of similar ethnic derivation. 
For each meta-analysis, chi-square tests for homogeneity 
and association were performed (14). The test for homogeneity 
tests for equality among the odds ratios obtained from the 
respective studies (the null hypothesis i  that the calculated 
odds ratios do not differ among the combined studies); the test 
for association assesses the level of significance ofan associa- 
tion between an allele and disease. Thus, with respect to each 
allele, p > 0.05 for the test for homogeneity and p < 0.05 for 
the test of association implies an overall association that can be 
inferred for all studies in the meta-analysis because the odds 
ratios were determined to be homogeneous. Overall odds 
ratios along with their 95% confidence intervals were calcu- 
lated and are presented for each recta-analysis. 
Identification and enrollment of patients with rheumatic 
heart disease and control subjects. In the present study, 
patients with rheumatic heart disease were identified from 
among patients referred to LDS Hospital for echoc~rdio- 
graphic studies who had typical findings of rheumatic valvular 
invokement and, on review, had a history and physical exam- 
ination censistent with rheumatic heart disease. Blood was 
drawn from these patients by venipuncture into heparinized 
tubes after verbal consent had been obtained, from patients and 
their physicians. The protocol was approved by the Institu- 
tional Review Board. Concurrent control subjects were se- 
lected at random from among blood bank donors. Samples of 
donor blood, identified by age and gender, were used for typing 
ill parallel with samples from patients. Typing was done by 
!aboratory personnel blinded to the source of sample (i.e., 
patient vs. control). 
Serologic determination of HI.A.DR alleles. Serologic typ- 
ing used the traditional microcytotoxicity assay in HLA trays 
(17). Lymphocytes were isolated from the "buffy coat" and 
separated into T- and B-cell populations by mixing with 
magnetic beads coated wifll monodonal ntibodies (anti-CD19 
and anti-CD8, respectively) (18). After removal of the super- 
natant and washing, the beads and cells bound to them were 
loaded onto standard microtiter HLA trays, and complement 
was added, followed by an acridine orange/ethidium bromide 
stain and the degree of cell lysis evaluated with a fluorescence 
microscope. 
DNA-based methods for class II allele determination. 
DNA was extracted from peripheral blood using a phenol- 
chloroform extraction procedure and adjusted to 200 ~g/ml. 
DR4 subtypes were defined by allele-specific oligonucleotide 
hybridization using a "dot-blot" procedure as follows: 
genomic DNA from DR4-positive patients was amplified (by 
the polymerase chain reaction technique) using generic DR4 
primers. The amplified DNA was denatured, spotted onto 
nylon membranes, bound by ultraviolet cross-linking and sue- 
cessively hybridized with phosphorus-32-1abeled o igonudeo- 
tide probes, each designed to detect the specific DR4 subtypes 
(i.e., Dw4, Dwl0, Dwl4 and Dwl5). After overnight hybrid- 
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Table 1. Characteristics of Patients in the 10 Studies Combined in the Meta-Analysis 
Study No. of No. of Matched DR Typing Mean Age 
(ref. no.) Race or Ethnic Group Pts Control Subjects Gender Method* Diagnosis 0'r)t 
Anastasiou-Nana et l. (5) American whites 33 82 42% male Commercial Chronic RHD 60 (24-84) 
Present study American whites 57 236 Unknown Commercial Chronic RHD Unknown 
Ayoub et al. (7) American whites 24 285 Unknown C,,mmercial Chronic RHD Unknown 
Maharaj et al. (12) South African blacks 103 220 33% male Local Chronic RHD 27.6 (12-60) 
Ayoub et al. (7) American blacks 48 64 Unknown Commercial Chronic RHD Unknown 
Taneja et al, (9) North Indian Hindus 52 163 Unknown Exchange Chronic RHD Unknown 
Jhinghan et al. (10) North Indian Hindus 110 134 Unknown Unknown Chronic RHD Unknown 
Rajapakse etal. (6) Saudi Arabian Arabs 40 100 40% male Commercial Chronic RHD/acute RF 21.4 (13-53) 
Guilherme et al. (11) Brazilian (mixed ethnic) 40 118 38% male Commercial Chronic RHD/acute RF 11 (5-53) 
Ozkan et al, (8) Turkish 107 203 40% male Commercial Chronic RHD 34,2 (17-58) 
*All studies determined DR specifieities by microeytotoxieity typing. [Numbers inparentheses are ranges. Commercial = commercially obtained typing sera; 
Exchange -- sera obtained by exchange from another typing center; Local = local sera for which specificities were determined at an international histocompatibility 
workshop; ref. = reference; RF = rheumatic fever; RHD = rheumatic heart disease. 
ization, the membranes were washed with 6× saline sodium 
citrate with 0.1% sodium dodecyl sulfate and placed on X-ray 
film to produce autoradiographs. 
Alleles at the DQA1, DQB1, and DPB1 loci were defined 
by scoring codige.~t.ed amplified fragment length polymor- 
phisms (19). Pe:tinent exons within each locus were amplified 
by the polymerasc hain reaction followed by digestion of the 
amplified DrqA t~y a combination of restriction enzymes. The 
fragments were separated by polyacrylamide gel electrophore- 
sis. This method provides unambiguous typing of heterozy- 
gotes because the phase (assignment to a particular haplotype) 
of the relevant restriction sites can be determined. 
Results 
Meta-analysis of published HLA.DR associations with 
rheumatic heart disease and concurrent series. Results of 
nine pubiished studies and those from a current, prospective 
series (n = 57 patients, n = 236 control subjects) were 
combined to obtain an overview of allele frequencies in cases 
of rheumatic heart disease using meta-analysis. These 10 
studies represent patients and control subjects of diverse 
ethnicity and race; however, within each study, patient and 
control samples were drawn from similar ethnic and racial 
groups. Table 1 contains the characteristics of each of the 
studies combined in the meta-analysis. Table 2 summarizes the 
Table 2. Odds Ratios [95% confidence intervals] Indicating Associations Between HLA-DR Alleles and Rheumatic Valvular Heart Disease 
As Determined for 10 Published Studies 
HI.A-DR Anastasiou-Nana Present Ayoub Maharaj Ayoub Taneja Jhinghan Rajapakse Guilherme Ozkan 
Allele et aL (5) Study et al. (7) et al. (12) et al. (7) et al. (9) et al. (10) et al. (6) et al. (11) et al. (8) 
DR1 0.65 1.03 0.44 5.15" 1.61 1.05 1.69 0.45 0.19 0.86 
[0.23-1.781 [0.46-2.271 [0.10-1.961 [1.90-14.01 [0.62-4.161 [0.42-2.641 [0.87-3.281 [0.17-1.201 [0.04-0.82] [0.43-1.751 
DR2 0,99 1.07 1.77 0.98 3.86 0.31" 0.32* 1.59 0.50 0.40 
[0.39-2.55] I0.57-2.021 [0.69-4.56] [0.57-1.711 [1.72-8.681 [0.15-0.64] [0.18-0.55] [0.75-3.35] [0.19-1,291 [0.20-0.821 
DR3 1.19 0.50 1.09 1.02 0.79* 1.96 2.83* 0.35 0.46 3.14" 
[0.49-2.881 [0.25-1.02] [0.35.-3.411 [0.62-1.671 [0.34-1.84] [1.03-3.73] [1.65-4.84] [0.14-0.86] [0.16-1.28] [1.90-5.17] 
DR4 2.29* 0.87 8.00* 1.12 2.02 1.58 0.63 13.6' 0.60 1.54 
[1.00-5.23] [0.47-1.62] [2.58-24.81 [0.56-2.25] [0.60-6.79] [0.80-3.091 [0.34-1.17] [5.61-33.01 [0.23-1.57] [0.94-2.55] 
DIL5 0.73 0,71 1.93 0.90 0.39* 0.24t 0.69 0.63 0.47 0.38* 
[0.22-2.441 [0.33-1,541 [0.70-5.31] [0.54-1.50] [0.16-0.91] [0.07-0.82] [0.37-1.311 [0.20-2.031 [0.20-1.04] [0.23-0.62] 
DR6 0.19' 0.91 0.70 2.55* 1.19 0.51 0.72 0.21 1.34 ND 
I0.04-0.851 [0.45-1.85] [0.20-2.49] [1.46-4.46] [0.49-2,88] [0.19-1.411 [0.36-1.461 [0.03-1.661 [0.56-3.231 
DR7 1.31 1.81 0.85 1.32 0.46 1.51 1.18 0,86 3.80* 2.69' 
[0.48-3.601 [0.96-3.401 [0.27-2.651 [0.67.-2.561 [01.~-!.381 [0.76-3.03] [0.66-2.14] [0.37-1.98] [1.80-8.03] I1.66-4.36] 
DR8 1.48 0.68 0.74 0.32 0.32 3.22 2.46 0.18 5.48 ND 
[0.40-5.431 10.19-2.401 [0.09-5.801 [0.09-1.101 [0.08-1.221 [0.44-23.51 I0.22-27.5] [0.01-3.26] [1.25-24.1] 
DR9 1.25 1.05 5.22 0.30 0.43 0.51 0.91 1.24 9.00 ND 
_ [0.11-14.3] [0.12-9.58] [0.52-52.8] [0.02-5.87] [0.06-2.80] [0.06-4.36] [0.20-4.16] [0.04-37.5] [0.36-225.] 
*Significant disease association for this allele reported in the published'study. "[Significant disease association before 
not done. correction for multiple comparisons. ND -- 
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Table 3. Meta-Analysis of Nine HLA-DR Alleles From 10 
Independent I vestigations 
Homogeneity Association OR 
Allele (p value) (p value) [95% Eli 
DR1 < 0.007 > 0,66 1.01 [0.76-1.34] 
DIL2 < 0.00001 < 0.04 0.82 [0.66-1.03] 
DR3 < 0.00001 < 0.007 1.08 [0.87-1.34] 
DR4 < 0.00001 < 0.0008 1.51 [1.20-1.90] 
DR5* > 0.09 < 0.00003 0.67 [0.53-0.84] 
DR6t < 0.008 > 0.64 0.99 [0.74-1.32] 
DR7 < 0.03 < 0,00005 1.37 [1.09-1,72] 
DRSt > 0.06 > 0.65 0,78 [0,46-1.32] 
DR9t > 0.69 > 0.97 0,91 [0.43--1.92] 
*DR5 was the only allele for which both significant homogeneity and 
association were found, i'These alleles were not examined in the Turkish study 
(Ozkan et al. [8]), and therefore the recta-analyses for these alleles combined 
data from only 9 of the 10 studies. CI = confidence interval; OR = odds ratio. 
odds ratios for each DR allele in each of the 10 investigations. 
These odds ratios were used to test for homog~,::eify among the 
results of the different studies and to test for association 
between the occurrence ofthe disease and the presence of one 
or more specific DR alleles. 
Results of the recta-analysis forthe 10 studies are presented 
in Table 3. The recta-analysis howed that the DR5 result was 
homogeneous among all studies (test for homogeneity, p > 
0.09) and that D1L5 was differentially expressed between 
patients and control subjects (test for association, p < 
0.00003). However, this was a negative association in that this 
antigen was underexpressed among patients compared with 
control subjects. Positive associations were observed for DR4 
(odds ratio [OR] 1.51, 95% confidence interval [CI] 1.20 to 
1.90, p < 0.0008) and DR7 (OR 1.37, 95% CI 1.09 to 1.72, p < 
0.00005). However, there was a very high degree of heteroge- 
neity among the 10 investigations with respect o these two 
alleles, suggesting that he positive associations were not found 
in all samples tested. 
In addition to the broad overview, additional recta-analyses 
were made by ethnic group. Seven investigations were grouped 
according to the ethnic background ofthe patients and control 
subjects; recta-analyses were then performed on these sub- 
groups. These findings are presented in Table 4. Among the 
studies of white subjects (n = 3), only DR4 was increased 
overall among patients with rheumatic heart disease (OR 1.74, 
95% CI 1.10 to 2.74, p < 0.03). However, there was significant 
heterogeneity of findings among these studies (p < 0.003), 
suggesting inconsistency in the DR4 association among whites. 
The two studies of black subjects howed an increase in 
DR1 (OR 2.80, 95% CI 1.40 to 5.57, p < 0.004) and DR6 (OR 
2.03, 95% CI 1.27 to 3.26, p < 0.003). A decrease in the DR8 
allele frequency was also seen for these combined studies (OR 
0.32, 95% CI 0.13 to 0.79, p < 0.02). No significant heteroge- 
neity was found for any of these three alleles, indicating that 
the HLA associations were consistent and homogeneous 
among studies for black subjects. 
In the two studies conducted with patients and control 
Table 4. Study Homogeneity and Disease Associations for HLA-DR 
Alleles As Determined byMeta-Analysis Within Studies Subgrouped 
by Race or Ethnic Derivation 
Study Homogeneity Association OR 
Population Allele (p value) (p value) [95% Cl] 
White DR4* < 0.003 < 0.03 1.74 [1.10-2,74} 
(n = 3) 
Black DRI > 0,09 < 0,004 2.80 [1.40-5,57] 
(n = 2) DR6 > 0,15 < 0,003 2.03 [1.27-3.26] 
DR8 > 0,98 < 0.02 0.32 [0.13-0.79] 
DR2 > 0,95 < 0.00001 0.31 [0.20-0.49 I 
DR3 > 0.38 < 0.00003 2,44 [1.62-3.69] 
DR5 > 0.11 < 0.05 0.52 [0.29-0.91] 
Indian 
(n = 2) 
*Significant heterogeneity for the DR4 odds ratios was found among the 
combined studies. Abbreviations as in Table 3. 
subjects drawn from North Indian Hindus, DIL5 was found to 
be decreased (OR 0.52, 95% CI 0.29 to 0.91, p < 0.05) and 
DR2 significantly underrepresented among the patients (OR 
0.31, 95% CI 0.20 to 0.49, p < 0.00001), whereas DR3 was 
overrepresented (OR 2.44, 95% CI 1.62 to 3.69, p < 0.00003). 
Tests for heterogeneity indicated that these allele frequencies 
were similar among the combined studies. 
Serologic typing f~r HLA-DR alleles in a prospective series 
of patients with rheumatic heart disease and control subjects. 
In the present study, an expanded series of serologic typing 
sera was used to examine recently identified "splits" of the 
previously defined serologic specificities. A nominally signifi- 
cant difference was noted only for DRwl7, which was de- 
creased in patients compared with control subjects (9.7% vs. 
15.7%, respectively, p < 0.05). This difference is not significant 
if correction ismade for multiple comparisons (20). 
Frequency of DQA, DQB and DPB alleles. The relative 
frequencies of alleles coding for the allelic alpha- and beta- 
chains of the HLA-DQ specificities (DQA and DQB) and the 
DP beta-chain alleles (DPB) were also examined inthe current 
series. The comparisons between patients and control subjects 
are shown in Table 5. The DQA*0103 allele was slightly 
elevated (10.8% vs. 5.0%), the DQB*0604 allele was slightly 
underrepresented (1.6% vs. 4.9%), and the DPB*0201 allele 
was underrepresented (7.8% vs. 14.5%) in patients compared 
with control subjects, respectively. These trends were not 
significant. The frequencies of other alleles were comparable 
in patients and control subjects. 
Discuss ion  
Summary of meta-analysis results for HLA-DR. Meta- 
analysis is a statistical approach that allows integration of 
findings from multiple investigations, thereby providing addi- 
tional analytic power not achievable when the individual 
studies are analyzed separately. In combining data from sev- 
eral studies it is important o be mindful of the inherent 
differences between the studies. Clearly the most marked 
difference among the 10 combined studies is the ethnic deri- 
vation of the patients and control groups. However, other 
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Table 5. Frequency ofDQA, DQB and DPA Alleles Among 
Control Subjects and Patients With Rheumatic Heart Disease 
Frequency 
Locus and Control Patients With 
Allele Subjects RHD 
DQA 
0191/0102 0.280 0.246 
0103 0.050 0.108 
0201 0.109 0.169 
0301 0.232 0.185 
0401 0.026 0.031 
0501 0.281 0.246 
DQB 
0201 0.253 0.230 
0301 0.211 0.213 
0302 0.111 0.131 
0303 0.064 0.033 
0501 0.088 0.148 
0602/0603 0.162 0.197 
0604 0.049 0.016 
DPB 
0101 0.052 0.094 
0201 0.145 0.078 
0301 0.130 0.156 
0401 0.423 0.344 
0402 0.132 0.203 
1101 0.036 - -  
RHD = rheumatic heart disease. 
sources of inhomogeneity may have influenced the overall 
findings. Among the possible sources of variability are patient 
and sample sizes (patient samples ranged from 24 to 110; 
control groups from 64 to 285), different sources of typing 
serum, the combining of patients with chronic rheumatic heart 
disease with those presenting with acute rheumatic fever in two 
of the studies, and the different mean age of patients in the 
respective studies (range 11 to 60 years). Despite these poten- 
tial sources of variability, the results of the meta-analysis for 
DR associations with rheumatic heart disease are generally 
consistent with the hypothesis of genetic factor(s) in the HLA 
region etiologically linked with rheumatic heart disease, par- 
ticularly within ethnically similar groups. Among these groups, 
homogeneity with respect to allele expression was observed. 
An overall HLA-DR aUelic association with rheumatic heart 
disease (protective ffect) was found to be imparted by the 
presence of DR5. The other DR alleles showed variable 
degrees of positive or negative association depending on the 
population tested. 
The DR5 protective ffect might be associated with ineffi- 
cient presentation f streptococcal peptides to relevant cells of 
the immune system. Alternatively, DR5 may be in linkage with 
another gene that imparts the protective ffect. Regardless of 
the underlying mechanism of this effect, its presence among 
many ethnic groups suggests that it has been conserved and 
supports a genetic basis for rheumatic heart disease. 
Me~a-analysis among ethnically s'.,milar sample popula- 
tions. Within subgroups divided by ethnic origin, aUelic asso- 
ciations with rheumatic heart disease were more frequently 
and consistently observed than tot the global meta-analysis. 
Significant associations were found for studies of subjects of 
African extraction (DR1, DR6, DR4) and significant yet 
different associations for subjects of Eastern Indian extraction 
(DR2, DR3, DP,5). Positive allele associations were found for 
the studies in white Americans (i.e., DR4 and DR7) but were 
heterogeneous. Only single studies were available for Arabian, 
Turkish and Brazilian (mixed ethnic) subjects. These ~tudies 
also reported positive DR associations (i.e., DR4 for Saudis, 
DR7 for Brazilians and Turks), but the results have not been 
replicated. 
The calculated odds ratios from the meta-analyses by ethnic 
derivation are in the range of 2 to 3 over control subjects for 
the positive associations and 0.3 to 0.5 for negative associa- 
tions. Although these odds ratios do not approach the odds 
ratio of 87.4 (for B27) reported for ankylosing spondylitis (the 
archetypal HLA-associated disease), they are in the range of 
odds ratios reported for myasthenia gravis (DR3, 2.5), Hashi- 
moto's thyroiditis (DR5, 3.2) or insulin-dependent diabetes 
(DR3, 3.2 and DR2, 0.2) (21). 
Explanation for diversity of findings. Several hypotheses 
could explain these observations: 1) There is a hierarchy 
among molecules of the major histocompatibility complex with 
respect o the successful presentation of a foreign peptide 
antigen to the immune system (22). Also, ->15 streptococcal 
strains, each with distinct M proteins, have been associated 
with outbreaks of rheumatic fever (23). Each different rheu- 
matogenic streptococcal strain might select for a particular DR 
allele(s) in the pathogenic process, resulting in a high propor- 
tion of patients positive for that particular allele during an 
outbreak. Therefore, the reported iversity of HLA associa- 
tions with rheumatic heart disease may partially reflect the 
involvement of multiple streptococcal peptides in the disease 
etiology. Within this scheme, heterogeneity would be further 
compounded by the fact that there are differences in allele 
frequencies among enetically distinct populations. Rheumatic 
heart disease could thus depend not only on genetically 
determined disease susceptibility, but also on the regional and 
temporal prevalence of a particular streptococcal strain(s). 
2) The existence of a rheumatic heart disease susceptibility 
gene(s) in linkage with an HLA allele(s) has been proposed. 
Some HLA alleles are extremely ancient (24); however, the 
high degree of polymorphism in the number of currently 
identified HLA alleles indicates that selective forces have 
guided the trend toward HLA diversity. It is possible that a 
gone (or genes) imparting susceptibility to rheumatic fever 
could have arisen in linkage with certain HLA alleles in the 
early human population. The subsequent generation of HLA 
polymorphism could have produced multiple haplotypes con- 
taining the susceptibility gene(s) in linkage with different HLA 
alleles. With time, random inactivating mutations in the sus- 
ceptibility gene(s) and crossover events link~.ng this gene(s) to 
other HLA alleles would further weaken the observed associ- 
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ation. Within a study population, the degree of linkage ob- 
sewed between rheumatic fever and an HLA allele would be a 
function of the genetic heterogeneity hat has arisen within the 
population since the origin of the susceptibility gene. 
hi our study, we observed the strongest association among 
the East Indian samples and to a somewhat lesser degree 
among black subjects (although the meta-analysis combined 
African and American blacks). The weakest associations were 
among American whites, who are the most genetically heter- 
ogeneous population of the three groupings. 
Rationale and results for DQ, DP genotyping. The DQB1 
and DQA1 loci are directly centromeric to the DRB1 locus on 
chromosome 6, so that an increased frequency of expression of 
a particular DR allele in patients should be reflected in a 
disproportionate frequency of associated DO genotypes 
among patients. We did not observe a definite increase in 
frequency of either DR serotypes or DO or DP alleles. These 
findings are consistent with one another but do not, by 
themselves, upport involvement of HLA alleles in the etiology 
of rheumatic heart disease among the limited group of Amer- 
ican whites. DNA-based studies of DQ and DP associations 
from the Eastern Indian and black groups were not available 
for inclusion in the meta-analysis. 
Conclusions. In the statistical overview, a consistent 
HLA-DR allelic association with rheumatic heart disease 
among all groups could be identified only for DR5 (a 
protective effect). However, within ethnically homogeneous 
groups, more consistent although differing DR associations 
were observed. These findings do support a genetic basis for 
rheumatic heart disease associated with the genes of the 
major histocompatibility complex; however, a unifying 
model for the pathoetiology for rheumatic heart disease 
could not be obtained. It appears that the HLA associations 
and possibly even etiologic mechanisms differ among ethnic 
groups and thus may depend on genetic, infectious, geo- 
graphic and temporal factors. These findings strongly sug- 
gest that for further studies in this area, subjects must be 
drawn from study samples of carefully defined genetic 
lineage and in the context of infecting organisms. The 
failure to do so will predictably result in the inconsistent 
findings that frequently characterize investigations of this 
kind. 
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